Individualized Management of Patients with Dry Eye Disease: Webinar 1
Media formats available:
Details
Presenters
Overview
This educational activity is supported by an independent medical educational grant from Shire. Learning Objectives
Upon completion of this activity, the participant should be able to: - Discuss the mechanism of action of dry eye disease.
- Evaluate the signs and symptoms in patients with dry eye complaints.
- Discuss the prevalence of dry eye disease.
- Develop a differential diagnosis for patients with complaints of dry eye.
Accreditation
EUROPEAN CREDIT The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the European Union of Medical Specialties (UEMS). Following the agreement on the mutual recognition of credits between the AMA and the UEMS-European Accreditation Council for CME, European physicians can earn ECMECs® by completing e-learning programs from accredited providers that have been certified for AMA PRA Category 1 Credits™.ACCREDITATION STATEMENTEvolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.CREDIT DESIGNATION STATEMENTEvolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participation Method
To receive credit for this activity, please be sure to access the complete the pre-test, post-test, and evaluation to receive your certificate. Faculty and Disclosures
DISCLOSURE POLICY
Professor Christophe Baudouin, MD, PhD, FARVO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Alcon, Dompe, Horus Pharma, Shire, Santen, and Thèa. Grant/Research Support: Horus Pharma, Santen, and Thèa. Professor Elisabeth Messmer, MD, FEBO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon/Novartis, Allergan, Dompe, Santen, Shire, Thèa, TRB-Chemedica, and Visufarma. Advisory Board/Speaker’s Bureau: Alcon/Novartis, Dompe, Santen, Shire, Thèa, TRB-Chemedica, and Visufarma. Grant/Research Support: Sylentis and Ursapharm. Editorial Support Disclosure Michelle Dalton, Writer, Susan Gallagher-Pecha, director of client services and project management, Evolve Medical Education LLC, and Erin Fletcher, MIT, director of compliance and education, Evolve Medical Education LLC, have no real or apparent conflicts of interest to report. Jaya Kumar, MD, peer reviewer has no conflict of interest to report.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMERThe views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Shire. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!